Summaries  by unknown
Volume 4 Issue 1 First Quarter 2011
summariEs
soLiD orGan transPLantation
Early versus late outset of lymphoproliferative 
disorders post-heart and lung transplantation: 
The PTLD.Int Survey
In a retrospective analysis of data for 288 individual patients 
from published studies, Khedmat and Taheri of the Baqiyatallah 
University of Medical Sciences and Dr. Taheri Medical Research 
Group, Tehran, Iran, found that early-onset PTLD patients were 
more likely to be of the B cell type. PTLD in early-onset patients 
was less likely to involve the skin and spleen but more likely to 
involve the respiratory tract. No difference was found between the 
two groups in survival rates. They suggest that all heart/lung graft 
recipients be evaluated for potential multiorgan disease.
ConDitioninG rEGimEns in LEuKEmia
Cyclophosphamide plus total body irradiation 
compared with busulfan plus cyclophosphamide as 
a conditioning regimen prior to hematopoietic stem 
cell transplantation in patients with leukemia: a 
systematic review and meta-analysis
Gupta and colleagues of the Advanced Centre for Treatment, 
Research and Education in Cancer, Tata Memorial Centre, 
Navi Mumbai, Maharashtra, India, did a systematic review and 
meta-analysis with overall survival and disease-free survival as 
the primary endpoints in a comparison of CYTBI vs BUCY as 
conditioning regimens. In the meta-analysis of seven random-
ized controlled trials involving 730 patients, the incidence of 
major complications between the the two regimens was not sig-
nificantly different, but TBI-based regimens were associated with 
more severe late effects on growth and development in children. 
Otherwise, the weight of the evidence favored CYTBI as a first-
choice conditioning regiment in patients with leukemia.
stEm CELL transPLantation
Age at transplantation and outcome after 
autologous stem cell transplantation in elderly 
patients with multiple myeloma
In a single-center, retrospective study, El Cheikh and colleagues 
of the Institut Paoli Calmettes, Marseille, France, compared out-
comes of 82 elderly (>65 years) and 104 younger (60 to 65 years) 
patients with multiple myeloma who had similar demographic 
features (other than age), disease characteristics and prognostic 
factors. In a multivariate analysis, age, melphalon dose, disease 
status of the transplant, had an impact of overall survival or trans-
plant-related mortality. They conclude that there is no biological 
justification for an age-discriminant policy for therapy of multiple 
myeloma.
